JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus

/PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing...

Related Keywords

Shanghai ,China ,A Bristol Myers Squibb ,James Li ,China National Medical Products Administration ,National Significant New Drug Development Program ,National Medical Products Administration ,Investigational New Drug ,New England Journal ,Nature Medicine ,Nat Rev ,Refractory Systemic Lupus ,Juno Therapeutics ,Bristol Myers Squibb ,Jw Therapeutics ,